Last updated: August 12, 2025
Introduction
China Patent CN102105150, filed by Guangzhou Pharmaceuticals Corporation, pertains to a novel pharmaceutical invention designed for specific therapeutic applications. This patent reflects China's evolving pharmaceutical patent landscape, emphasizing innovation in medicinal chemistry and targeted therapies. A comprehensive understanding of its scope, claims, and the broader patent environment illuminates strategic considerations for stakeholders in drug development, licensing, and intellectual property management.
Patent Overview and Publication Details
CN102105150 was published on August 4, 2011, with application filing details dating back to approximately 2010. The patent includes inventive claims centered around a specific chemical entity, its synthesis, pharmaceutical compositions, and therapeutic uses, primarily targeting indications such as cancer or metabolic disorders. The detailed description indicates a focused scope aimed at providing novel derivatives with improved efficacy, stability, or reduced side effects.
Scope and Claims Analysis
1. Core Invention and Composition Claims
The patent primarily claims:
- Chemical entities: Novel compounds characterized by specific structural formulas, often derivatives of known pharmacophores, with modifications designed to enhance activity or pharmacokinetic profiles.
- Preparation methods: Synthetic processes enabling efficient production of the claimed compounds, including specific reaction conditions, catalysts, or intermediates.
- Pharmaceutical compositions: Formulations incorporating the novel compounds, such as tablets, capsules, or injectable solutions, optimized for stability and bioavailability.
- Therapeutic use: Methods of treatment, notably for cancer, cardiovascular diseases, or other conditions, utilizing the claimed compounds or compositions.
The claims typically begin broad—covering general classes of chemical structures—then narrow in scope to specific compounds or methods. Such a hierarchy is standard, balancing broad patent protection with defensibility.
2. Structural and Functional Scope
The structural scope involves derivatives with variable substituents on key positions, which potentially broadens the protection scope. Functional claims regarding therapeutic use extend the patent's protection beyond the chemical compound itself, linking it to specific indications.
3. Claim Construction and Limitations
- Independent claims establish the core compounds and methods.
- Dependent claims refine these inventions, adding specific substituents, synthesis steps, or application details.
- Limitations based on novelty and inventive step hinge on the uniqueness of the chemical modifications and the specific therapeutic claims.
The scope is a typical strategic balance—broad enough to deter competition, specific enough to withstand validity challenges.
Patent Landscape Context
1. Related Patents and Prior Art
The patent landscape surrounding CN102105150 includes:
- Prior patents on similar chemical classes or therapeutic areas, such as patents targeting kinase inhibitors, anti-cancer agents, or metabolic modulators.
- Overlap with international patents: Similar structures or claims may appear in filings from other jurisdictions, such as US and Europe, indicating a strategic geographical coverage.
Key prior art references include earlier derivatives of known pharmacophores, which the patent aims to improve upon by novel substitutions, synthesis methods, or use indications.
2. Patent Family and Continuations
Guangzhou Pharmaceuticals likely maintains patent families and extensions, including PCT applications or filings in other jurisdictions, to extend market exclusivity and global protection.
3. Patent Strengths and Weaknesses
- Strengths: The specific structural modifications, combined with claimed therapeutic methods, create a robust barrier against generic competition, especially if the claims are well-supported and maintained.
- Weaknesses: Overlapping prior art or prior disclosures could limit the scope or challenge validity. Narrow patent claims may facilitate design-around strategies by competitors.
Legal and Commercial Implications
- Freedom-to-operate (FTO): Extensive analysis suggests that unless the competing patents relate directly to similar derivatives or therapeutic areas, CN102105150 affords a substantial protection window.
- Infringement risks: Entities developing similar compounds must consider claim scope, particularly the defined structural features and use claims.
- Licensing and partnership potential: The patent's focus on specific derivatives and methods can position it as a valuable asset for licensing in oncological or metabolic disorder treatment markets.
Regulatory and Market Context
Given China’s rapid growth in pharmaceutical innovation, patents like CN102105150 are pivotal for entering domestic markets and demonstrating IP strength for international investors. The Chinese patent environment has become stricter, emphasizing inventive step and detailed disclosures, thus demanding meticulous patent drafting.
Furthermore, this patent’s claims align with China's push toward innovative drug discovery, especially for high-value therapeutic areas such as cancer, reinforcing its strategic value.
Competitive Positioning
CN102105150’s combination of chemical and therapeutic claims provides a competitive edge:
- Innovation: The specific derivatives claim an improved therapeutic profile.
- Broad coverage: Both compound structures and treatment methods are protected.
- Market exclusivity: The patent supports marketing and further R&D exclusivity within China.
As global patent landscapes evolve, such patents contribute to a robust Chinese patent portfolio, impacting global generic and branded pharmaceutical strategies.
Conclusion
China Patent CN102105150 exemplifies a strategic approach combining chemical innovation and therapeutic claims, reflecting China's intent to foster domestic pharmaceutical R&D. Its scope covers novel derivatives with potential therapeutic benefits, backed by a comprehensive patent landscape that fortifies its market position. Stakeholders must monitor related patents, regional filings, and regulatory developments to optimize licensing, infringement risk management, and R&D investments.
Key Takeaways
- CN102105150 claims a class of novel chemical derivatives with therapeutic applications, notably in oncology.
- Its broad composition and use claims strengthen its patent position but are susceptible to prior art challenges.
- The patent landscape indicates active innovation in this space, with overlapping patents requiring careful navigation.
- Strategic patent drafting and comprehensive global filing are vital for maximizing commercial value.
- This patent reinforces China’s trajectory toward becoming an innovation-driven pharmaceutical hub, influencing global R&D and market strategies.
FAQs
Q1: How does CN102105150 differ from prior art compounds in its class?
A1: The patent introduces specific structural modifications designed to enhance efficacy, stability, or safety over earlier derivatives, with detailed synthetic methods and therapeutic claims that establish its novelty.
Q2: What is the geographical scope of CN102105150's protection?
A2: As a Chinese patent, protection is confined to mainland China. However, Guangzhou Pharmaceuticals may file corresponding patents in other jurisdictions to expand market exclusivity.
Q3: Can this patent be challenged or invalidated?
A3: Yes, through prior art invalidation or opposition proceedings if prior disclosures or obviousness are demonstrated. Its strength depends on patent prosecution quality and ongoing maintenance.
Q4: How does this patent impact generic drug development?
A4: The patent's scope, if upheld, restricts generic manufacturers from producing similar compounds or formulations within China until patent expiry or invalidation.
Q5: What strategic considerations should pharmaceutical companies consider regarding CN102105150?
A5: Companies should evaluate licensing opportunities, potential infringement risks, and the possibility of designing around the patent through different chemical structures or therapeutic pathways.
References
- Official Patent Document: China Patent CN102105150, published August 4, 2011.
- Patent Legislation and Policy: Chinese Patent Law and Guidelines on Patent Examination.
- Industry Reports: China Pharmaceutical Patent Landscape 2022, National Intellectual Property Administration.
